P&G OTC sales up 2%, paced by Pepto, Metamucil, but offset by 6% oral care sales drop.
This article was originally published in The Tan Sheet
Executive Summary
P&G PEPTO-BISMOL, METAMUCIL DRIVE 2% OTC VOLUME GROWTH in North America for the company's second quarter of FY 1998 (ended Dec. 31), Procter & Gamble Assistant Treasurer James Prevost told securities analysts during a Jan. 27 conference call. However, total health care volume dropped 2% because a 6% decline in oral care products sales was only partially offset by gains in sales of OTCs such as the Vicks line of cough/cold products, Pepto and Metamucil, Prevost noted.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: